All In Biotech

Drug Trial Radar · NCT02365597

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

239

Actual

Start

Apr 22, 2015

Primary completion

Sep 15, 2022

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Feb 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the objective response rate (complete response \[CR\]+ partial response \[PR\]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

Conditions

  • Urothelial Cancer

Interventions

  • ErdafitinibDrug

    8 mg orally once daily for 28 days on a 28 day cycle.

  • MidazolamDrug

    Participants who enrolled in DDI substudy will receive pretreatment with single dose of midazolam on Day -2 and single dose of midazolam on Day 13.

  • MetforminDrug

    Participants who enrolled in DDI substudy will receive pretreatment with single dose of metformin on Day -1 and single dose of metformin on Day 14.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Study: Percentage of Participants With Best (Overall) Objective ResponseTime frame: From Cycle 1 Day 1 up to 6 years 2 months
  2. Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose
  3. Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
  4. Drug-Drug Interaction (DDI) Substudy: Maximum Observed Plasma Concentration (Cmax) of Metformin Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
  5. Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Midazolam Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
  6. Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
  7. Drug-Drug Interaction (DDI) Substudy: Time to Reach the Maximum Observed Plasma Concentration (Tmax) of Metformin Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
  8. Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Midazolam Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
  9. Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
  10. Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC[0-last]) of Metformin Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)
  11. Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Midazolam Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
  12. Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of 1-OH-Midazolam (Midazolam Metabolite) Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -2 (predose) up to Day 13 post dose (each cycle length=28 days)
  13. Drug-Drug Interaction (DDI) Substudy: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Infinite Time (AUC[0-Infinity]) of Metformin Alone or in Combination With ErdafitinibTime frame: Cycle 1 Day -1 (predose) up to Day 14 post dose (each cycle length=28 days)

Locations

105 sites in 15 countries. Site status is shown where the registry gives one.

  • Site not named

    Sedona, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Orange, California

  • Site not named

    Sacramento, California

  • Site not named

    Stanford, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Chicago, Illinois

  • Site not named

    Iowa City, Iowa

  • Site not named

    Louisville, Kentucky

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Omaha, Nebraska

  • Site not named

    Las Vegas, Nevada

  • Site not named

    New York, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Medford, Oregon

  • Site not named

    Tualatin, Oregon

  • Site not named

    Hershey, Pennsylvania

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Myrtle Beach, South Carolina

  • Site not named

    Nashville, Tennessee

  • Site not named

    Dallas, Texas

  • Site not named

    Denton, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Hampton, Virginia

  • Site not named

    Graz, Austria

  • Site not named

    Linz, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Aalst, Belgium

  • Site not named

    Brussels, Belgium

  • Site not named

    Charleroi, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Wilrijk, Belgium

  • Site not named

    Angers, France

  • Site not named

    Bordeaux, France

  • Site not named

    Caen Cédex 05, France

  • Site not named

    Dijon, France

  • Site not named

    Lyon, France

  • Site not named

    Nice, France

  • Site not named

    Nîmes, France

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.